GlassScriptPhysician profile
Dagny Marie Davis
NPI 1962170845
$2,291.02
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $1,511 · 2023: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.38 | 2021-2023 | |
| Novo Nordisk INC | $343.31 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $307.62 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Currax Pharmaceuticals LLC | $191.12 | 2021-2022 | |
| Antares Pharma, INC. | $125.57 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $106.59 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.53 | 2022-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $90.36 | 2022 | |
| Sunovion Pharmaceuticals INC. | $77.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $66.08 | 2022-2023 | Breztri |
| Abbott Laboratories | $60.38 | 2022-2023 | Freestyle Libre 2 |
| Nestle Healthcare Nutrition INC. | $46.95 | 2022 | |
| Dexcom, INC. | $37.05 | 2022-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $31.19 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $19.78 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.39 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.92 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.08 | 2022 | |
| Bioventus LLC | $14.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.16 | 2022 | |
| Becton, Dickinson and Company | $13.03 | 2023 | Bd Onclarity |
| Idorsia Pharmaceuticals US INC | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dagny Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.